Webinar
The terms placebo and nocebo are well known. Is there a missing third component to these phenomena? Is there a missing component of the subjective experience that has not previously been labelled or studied and that it is more relevant that previously due to the arrival of long-acting injectable buprenorphine preparations.
Mark Daglish is Director of Addiction Psychiatry, Royal Brisbane & Women's Hospital. In addition to being the Director of HADS at RBWH, Mark is also a senior staff specialist in Roma St and Melaleuca opioid clinics.